BACKGROUND: High levels of activated protein–inhibitor complexes of the intrinsic coagulation proteins are associated with ischemic stroke (IS) but not with myocardial infarction (MI). This study was aimed at determining whether the antigen levels of coagulation factors(factor XII, FXII, and FXI and prekallikrein (PK)are associated with MI and IS, and whether this association is independent of levels of activated protein–inhibitor complexes. PATIENTS AND METHODS: The RATIO study included young women (< 50 years) with MI (N = 205)and IS (N = 175), and 638 healthy controls. Antigen levels of FXII, FXI and PK were measured and expressed as percentages of of those in pooled normal plasmas. Odds ratios (ORs) and corresponding 99% confidence intervals (CIs) were calculated for high levels (i.e. ≥ 90th percentile of controls) as measures of rate ratios. RESULTS: After adjustment for potential confounders, high levels of FXII antigen were not associated with MI risk or IS risk(OR(MI) 1.18, 99% CI 0.51–2.74; ORIS 1.03, 9% CI 0.41–2.55). High levels of FXI antigen were slightly associated with an increase in MI risk (OR(MI) 1.55, 9% CI 0.74–3.21), whereas there was a substantial association with IS risk (ORIS 2.65, 9% CI 1.27–5.56). PK antigen was slightly associated with MI risk but not with IS risk(ORMI 1.54, 9% CI 0.67–3.52; ORIS 0.90, 9% CI 0.35–2.33). All associations remained similar after adjustment for levels of protein–inhibitor complexes. CONCLUSION: Increased levels of FXI antigen were associated with an increase in IS risk, whereas they showed only a marginal association with MI risk. FXII antigen and PK antigen levels were not substantially associated with MI risk and IS risk.
BACKGROUND: High levels of activated protein–inhibitor complexes of the intrinsic coagulation proteins are associated with ischemic stroke (IS) but not with myocardial infarction (MI). This study was aimed at determining whether the antigen levels of coagulation factors(factor XII, FXII, and FXI and prekallikrein (PK)are associated with MI and IS, and whether this association is independent of levels of activated protein–inhibitor complexes. PATIENTS AND METHODS: The RATIO study included young women (< 50 years) with MI (N = 205)and IS (N = 175), and 638 healthy controls. Antigen levels of FXII, FXI and PK were measured and expressed as percentages of of those in pooled normal plasmas. Odds ratios (ORs) and corresponding 99% confidence intervals (CIs) were calculated for high levels (i.e. ≥ 90th percentile of controls) as measures of rate ratios. RESULTS: After adjustment for potential confounders, high levels of FXII antigen were not associated with MI risk or IS risk(OR(MI) 1.18, 99% CI 0.51–2.74; ORIS 1.03, 9% CI 0.41–2.55). High levels of FXI antigen were slightly associated with an increase in MI risk (OR(MI) 1.55, 9% CI 0.74–3.21), whereas there was a substantial association with IS risk (ORIS 2.65, 9% CI 1.27–5.56). PK antigen was slightly associated with MI risk but not with IS risk(ORMI 1.54, 9% CI 0.67–3.52; ORIS 0.90, 9% CI 0.35–2.33). All associations remained similar after adjustment for levels of protein–inhibitor complexes. CONCLUSION: Increased levels of FXI antigen were associated with an increase in IS risk, whereas they showed only a marginal association with MI risk. FXII antigen and PK antigen levels were not substantially associated with MI risk and IS risk.
Authors: Romil R Parikh; Aaron R Folsom; Jeffrey R Misialek; Wayne D Rosamond; Patricia P Chang; Weihong Tang; Mary Cushman Journal: Thromb Res Date: 2019-08-22 Impact factor: 3.944
Authors: Duke Appiah; Oluwaseun E Fashanu; Susa R Heckbert; Mary Cushman; Bruce M Psaty; Aaron R Folsom Journal: Blood Coagul Fibrinolysis Date: 2017-07 Impact factor: 1.276
Authors: Bengt Sennblad; Saonli Basu; Johanna Mazur; Pierre Suchon; Angel Martinez-Perez; Astrid van Hylckama Vlieg; Vinh Truong; Yuhuang Li; Jesper R Gådin; Weihong Tang; Vera Grossman; Hugoline G de Haan; Niklas Handin; Angela Silveira; Juan Carlos Souto; Anders Franco-Cereceda; Pierre-Emmanuel Morange; France Gagnon; Jose Manuel Soria; Per Eriksson; Anders Hamsten; Lars Maegdefessel; Frits R Rosendaal; Philipp Wild; Aaron R Folsom; David-Alexandre Trégouët; Maria Sabater-Lleal Journal: Hum Mol Genet Date: 2017-02-01 Impact factor: 6.150
Authors: N C Olson; S Butenas; L A Lange; E M Lange; M Cushman; N S Jenny; J Walston; J C Souto; J M Soria; G Chauhan; S Debette; W T Longstreth; S Seshadri; A P Reiner; R P Tracy Journal: J Thromb Haemost Date: 2015-09-14 Impact factor: 5.824
Authors: Anh T P Ngo; Kelley R Jordan; Paul A Mueller; Matthew W Hagen; Stéphanie E Reitsma; Cristina Puy; Alexey S Revenko; Christina U Lorentz; Erik I Tucker; Quifang Cheng; Monica T Hinds; Sergio Fazio; Brett P Monia; David Gailani; András Gruber; Hagai Tavori; Owen J T McCarty Journal: J Thromb Haemost Date: 2021-02-10 Impact factor: 5.824
Authors: Ludvig B Rinde; Birgit Småbrekke; Ellisiv B Mathiesen; Maja-Lisa Løchen; Inger Njølstad; Erin M Hald; Tom Wilsgaard; Sigrid K Brækkan; John-Bjarne Hansen Journal: J Am Heart Assoc Date: 2016-11-07 Impact factor: 5.501
Authors: Jeannette Simino; Zhiying Wang; Jan Bressler; Vincent Chouraki; Qiong Yang; Steven G Younkin; Sudha Seshadri; Myriam Fornage; Eric Boerwinkle; Thomas H Mosley Journal: PLoS One Date: 2017-07-13 Impact factor: 3.240